Program

TUESDAY MAY 22, 2001

7:00-8:00	Breakfast with the Experts Donald Patrick PhD, MSPH, Professor, University of Washington, Seattle, Washington, USA Topic: Quality of Life Assessment and FDA Claims Kevin Schulman MD, Director, Duke Clinical Research Institute Center for Clinical and Genetic Economics, Durham, North Carolina, USA Topic: Cost-effectiveness Analysis, Genetics and Cross-national Comparisons Michael Drummond PhD, Director, University of York Centre for Health Economics, York, UK Topic: International Requirements for Reimbursement, Pricing and Adoption George Torrance PhD, Vice President, Innovus Research, Burlington, Ontario, Canada Topic: Cost-utility Analyses and Preference Assessment
8:00-10:00	Incoming Presidential Address Eva Lydick PhD 2001-2002 ISPOR President and Director of Epidemiology, AstraZeneca Inc, Wilmington, Delaware, USA Awards Presentations Presentation of ISPOR Service Awards Presentation of ISPOR Distinguished Service Awards Presentation of the PhRMA Foundation Faculty Development Awards in Pharmacoeconomics Presented by: Del Persinger, President and CEO, Pharmaceutical Research Manufacturers Association (PhRMA) Foundation and Jean Paul Gagnon PhD, PhRMA Foundation Pharmacoeconomics Advisory Committee Chair Awardees: Jennifer H. Lofland PharmD, Thomas Jefferson University Medical College, Philadelphia, PA, USA David L. Veenstra PhD, University of Washington School of Pharmacy, Seattle, WA, USA Second Plenary Session - "Bias in Pharmacoeconomic Studies: A Debate on the JAMA Articles" Objectives: To summarize the findings of the bias articles in JAMA; to spark a lively debate about the JAMA editorial opinions accompanying the articles; to consider the impact of the research on industry use of Pharmacoeconomics. Moderator: Sean Sullivan PhD, ISPOR Annual Meeting Program Chair and Associate Professor, University of Washington, Seattle, Washington, USA Speakers: Suzanne R. Hill BMed, PhD, FAFPHM, Discipline of Clinical Pharmacology, Newcastle Mater Hospital & Faculty of Medicine & Health Sciences, The University of New South Wales, Newcastle, Australia Drummond Rennie MD, Professor of Medicine, University of California-San Francisco & Deputy Editor, JAMA - The Journal of the American Medical Association, Jacksonville, Oregon, USA Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses, JAMA 2000; 283(16) http://jama.ama-assn.org/issues/v283n16/abs/joc91361.html Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them credible, JAMA 2000; 283(16) http://jama.ama-assn.org/issues/v283n16/ffull/jed00027.html
10:00-10:30	Poster Presentations - Session 2 Economic, clinical, quality of life, and preference-based assessment study results on the following diseases and topics will be displayed: Infectious Disease (PID), Mental Health (PMH), Pain & Neurological Disorders (PPN), Urinary & Kidney Disorders (PUR), Women's & Men's Health (PWM), No Specific or Multiple Diseases-Health Policy (PHP), No Specific or Multiple Diseases-Quality of Life & Preference-based Measures (PQP), No Specific or Multiple Diseases-Methodological Advances (PMA)
10:30-12:00	Podium Sessions CANCER CN1 UTILITIES OF METASTATIC BREAST CANCER PATIENTS (PT.) TREATED WITH TAXANES COMPARED TO UTILITIES OF ONCOLOGY NURSES (NUR) Hauser R13, Theriault R2, Wilson J3, Shepherd M3, Lawson K3, Koeller J3, 1Abt Associates Clinical Trials, Cambridge, MA, USA; 2University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; 3University of Texas, Austin, TX, USA CN2 EFFECT OF INCLUDING (VERSUS EXCLUDING) FATES WORSE THAN DEATH ON UTILITY MEASUREMENT Franic DM1, Pathak DS2, 1The University of Georgia, Athens, GA, USA; 2The Ohio State University, Columbus, OH, USA CN3 COST-EFFECTIVENESS ANALYSIS OF IRINOTECAN+5FU/FA ALONE AS FIRST-LINE THERAPY IN ADVANCED COLORECTAL CANCER IN THE UK Brown R1, Sorensen S1, Burrell A2, Bearne A2, 1MEDTAP International Inc, Bethesda, MD, USA; 2Aventis Pharma, Kent, UK CN4 ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER CISPLATIN BASED TREATMENTS FOR NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK Botwood N1, McKendrick J1, Aristides M2, Lees M2, Maniadakis N3, Wein W3, Stephenson D1, 1Eli Lilly, Basingstoke, UK; 2M-TAG, London, UK; 3Eli Lilly, Windlesham Surrey, UK CARDIOVASCULAR DISEASE, SESSION 1 CV1 THE VALUE OF COMPLIANCE: EVIDENCE FROM TWO PATIENT COHORTS McGuigan KA, Sokol M, Yao J, Haynes J, Qian Q, Boscarino J, Epstein R, Merck-Medco Managed Care, LLC, Franklin Lakes, NJ, USA CV2 INDIRECT COMPARISONS OF DRUGS USING META-ANALYSIS: VALIDATION OF RESULTS Ross SD1, Klawansky S1, Allen IE2, 1MetaWorks, Medford, MA, USA; 2Babson College, Wellesley, MA, USA CV3 DO SHORT-ACTING OPIATES IN OFF-PUMP BYPASS SURGERY REDUCE LENGTH OF STAY OR TOTAL HOSPITAL COSTS Reddy P1, Feret B2, Kulicki L2, Jordan S2, Donahue S2, Quercia R2, 1University of Connecticut, Storrs, CT, USA; 2Hartford Hospital, Hartford, CT, USA CV4 USING UK OBSERVATIONAL DATA TO IDENTIFY POSSIBILITIES FOR THE COST-EFFECTIVE IMPROVEMENT OF THE TREATMENT OF ATRIAL FIBRILLATION Piercy J1, James P2, Baum D3, Kuester L3, 1Mapi Values, Macclesfield, UK; 2CHKS Ltd, Alcester, UK; 3Solvay Pharmaceuticals, Hannover, Germany DIABETES/GASTROINTESTINAL DISORDERS DG1 THE RELATIONSHIP OF DIABETES SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE Pfalzgraf AR, Nau DP, West Virginia University, Morgantown, WV, USA DG2 THE INCREMENTAL COST OF DIABETES IN CHRONIC ILLNESS CO-OCCURRENCES Garis RI1, Farmer KC2, Arora M1, 1Creighton University, Omaha, NE, USA; 2University of Oklahoma, Oklahoma City, OK, USA DG3 A RETROSPECTIVE EVALUATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED GASTROINTESTINAL COMPLICATIONS AMONG ADULTS IN A MANAGED CARE HEALTH PLAN Dodd MA1, D'Angio R2, Gupchup GV1, Nelson C3, 1The University of New Mexico, Albuquerque, NM, USA; 2Pfizer Inc, Cedar Crest, NM, USA; 3Presbyterian Healthcare Services, Albuquerque, NM, USA DG4 DISEASE SEVERITY DETERMINES COST OF GASTROESOPHAGEAL REFLUX DISEASE IN A MIDWEST USA HEALTHCARE PLAN Brelje T1, Heaton A1, Martin S1, Bhattacharjya A2, Dodd S2, Thornhill J2, 1Prime Therapeutics, Inc, Eagan, MN, USA; 2Janssen Pharmaceutica Products, Titusville, NJ, USA INFECTIOUS DISEASE ID1 DEVELOPMENT OF A STOCHASTIC DECISION ANALYSIS MODEL OF TREATMENT OF PYELONEPHRITIS FROM THE RESULTS OF AN RCT Davey P1, Wang J1, Claxton K2, Fenwick E2, Sculpher M2, Talan D3, 1University of Dundee, Dundee, UK; 2University of York, York, UK; 3Olive View-UCLA Medical Centre, Sylar, CA, USA ID2 HEALTH VALUES FOR THE LIPODSYTROPHY SYNDROME Lenert LA1, Fedderson M2, Sturley A2, Lee D1, 1University of California-San Diego, San Diego, CA, USA; 2San Diego VA Research Foundation, San Diego, CA, USA ID3 COST-EFFECTIVENESS ANALYSIS OF AN INTRANASAL INFLUENZA VACCINE FOR HEALTHY CHILDREN Luce B1, Zangwill K2, Palmer C1, Mendelman P3, Yan L4, Wolff M4, Cho I3, Iacuzio D5, Belshe B6, 1MEDTAP International Inc, Bethesda, MD, USA; 2Harbor-UCLA Medical Center, Torrance, CA, USA; 3Aviron, Mountain View, CA, USA; 4The EMMES Corporation, Potomac, MD, USA; 5Roche Pharmaceuticals, Nutley, NJ, USA; 6St. Louis University, St. Louis, MO, USA ID4 THE CONFUSION BETWEEN SEPTICEMIA AND SEVERE SEPSIS Linde-Zwirble WT1, Ball DE2, Cooper LM2, Lidicker J1, Angus DC3, 1Health Process Management, Owings Mills, MD, USA; 2Eli Lilly and Company, Indianapolis, IN, USA; 3University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
12:00-1:30	Poster Presentations - Session 2, Exhibits and Lunch
1:30-3:00	Issues Panels Model-based Analysis in a World of Evidence-based Medicine Chair: A. David Paltiel PhD, Yale School of Medicine, New Haven, CT, USA Frontiers in Meta-analysis Chair: Joseph Cappelleri PhD, MPH, Pfizer, Groton, CT, USA Pharmacoeconomics & Pharmacogenomics Chair: David Veenstra PharmD, PhD, University of Washington, Department of Pharmacy, Seattle, WA, USA Reference Pricing Chair: Haiden Huskamp PhD, Harvard Medical School, Department of Health Care Policy, Boston, MA, USA
3:00-3:30	Break
3:30-5:00	ISPOR Standards of Practice in Pharmacoeconomics and Outcomes Research OPEN FORUM Good Modeling Research Practices presented by ISPOR Task Force Chair, Milton Weinstein PhD, Professor Health Policy & Management, Harvard School of Public Health, Center for Risk Analysis, Boston, Massachusetts, USA Good Research Practices in Prospective Studies presented by ISPOR Task Force Chair, Louis Morris PhD, President, Louis A. Morris & Associates, Dix Hills, New York, USA Good Research Practices in Retrospective Database Studies presented by ISPOR Task Force Chair, Brenda Motheral RPh, PhD, MBA, Senior Director of Outcomes Research, Express Scripts Inc, Maryland Heights, Missouri, USA Good Research Practices in Quality of Life and Preference-based Measurement Studies presented by ISPOR Task Force Chair, Paul Kind MPhil, Senior Research Fellow, University of York, Centre for Health Economics, York, UK
5:00-6:00	ISPOR Business Meeting & Discussion of ISPOR Code of Ethics Presiding: Jon C. Clouse RPh, MS, ISPOR 2000-2001 President and Executive Vice President, Ingenix Pharmaceutical Services, Eden Prairie, Minnesota, USA ISPOR Code of Ethics Presented by: ISPOR Task Force Chair, Francis Palumbo PhD, JD, University of Maryland Center on Drugs & Public Policy, Baltimore, Maryland, USA
6:00-7:00	QUALITY OF LIFE SPECIAL INTEREST GROUP DISCUSSIONS & RECEPTION - TRACK 3 During this session, informal discussions of quality of life outcomes issues (presented during the Quality of Life Open Forum held Monday, May 21 from 5:30 to 6:30) will continue and development of practical solutions will be considered.

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2008 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.